PAVmed (PAVM) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Ascendiant Capital | Maintained | Buy | $57.00 from $56.00 | Aug 27, 2026 |
| Ascendiant Capital | Maintained | Buy | $56.00 from $65.00 | Jun 8, 2026 |
| Ascendiant Capital | Maintained | Buy | $65.00 from $510.00 | Apr 9, 2026 |
| Ascendiant Capital | Maintained | Buy | $17.00 from $20.00 | Dec 10, 2025 |
| Ascendiant Capital | Maintained | Buy | $20.00 from $19.00 | Oct 6, 2025 |
| Ascendiant Capital | Maintained | Buy | $19.00 from $19.50 | Jun 6, 2025 |
| Ascendiant Capital | Maintained | Buy | $19.50 from $19.00 | Apr 21, 2025 |
| Ascendiant Capital | Maintained | Buy | $19.00 from $21.00 | Dec 9, 2024 |
| Cantor Fitzgerald | Maintained | Neutral | $1.40 | Aug 18, 2023 |
Frequently asked questions
Is PAVM a buy, sell, or hold?
Analysts covering PAVmed currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on PAVM?
On Aug 27, 2026, Ascendiant Capital maintained PAVmed at Buy with a price target of $57.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.